<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630913</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2018-03</org_study_id>
    <nct_id>NCT03630913</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma</brief_title>
  <acronym>GANEA3</acronym>
  <official_title>Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Direction Générale de l'Offre de Soins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel lymph node dissection (SLND) after NAC, aimed to reduce the rate of unnecessary
      axillary lymphadenectomy, is not a standard of care in case of patient with previously
      involved node before NAC because of a too high false negative rate (FNR).

      Clinical consequences of FNR of SLND after NAC are currently unknown. Consequently, contrary
      to adjuvant setting, a risk of SLND false negative case after NAC is not acceptable.

      GANEA3 aims to evaluate the results of an innovative multiparametric strategy combining (1)
      an identification before chemotherapy of a lymph node involvement using a metal clip and then
      its analysis after treatment, (2) the analysis of sentinel lymph node (SLN) after NAC, and
      (3) analysis of biological parameters of breast tumor before and after NAC, to predict
      axillary status after NAC. This will identify patients with initial lymph node involvement
      who could benefit from SLN after NAC without additional axillary dissection with a very low
      FNR (≤1%).

      The most &quot;pathological&quot; metastatic lymph node will be identified with a metal clip under
      ultrasound. They will then receive a NAC before breast and axillary surgery. An assessment of
      the NAC response at the breast and axillary will be performed by imagery. Then, all patients
      undergo the resection of the tagged axillary node with the metal clip, SLN detection and
      biopsy and a complementary axillary lymphadenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GANEA3 is a prospective multicenter diagnostic study assessing the benefit of targeting
      initial involved node in complement to SLND and breast tumor characteristics to predict
      axillary status after NAC.

      The diagnostic performances of this strategy will be primarily assessed by the decrease of
      the FNR with the combined strategy compared to SLND alone.

      The primary objective is to evaluate the interest of identifying, before NAC, the initial
      involved lymph node to improve the prediction of axillary status after NAC.

      The main secondary objectives are :

        -  To assess the feasibility, at the time of the surgery, of the identification and
           resection of the initially involved lymph node, tagged with the metal clip before NAC ;

        -  To evaluate the complications related to the setting up of the metal clip for the
           identification of a lymph node metastatic ;

        -  To evaluate the interest and impact of immunohistochemical analysis of tagged lymph node
           and SLN ;

      Patients treated for a large early breast cancer (BC) needing NAC undergo axillary sonography
      assessment routinely performed to seek suspicious nodes. When several suspicious nodes are
      found only the worst is chosen. A fine needle aspiration is performed to allow cytological
      examination (biopsy is optional) of the suspicious node. In case of proven axillary
      involvement, the patient is informed about GANEA 3 study in order to be included.

      At this step the patient must accept the study and sign the consent form. The involved node
      is then tagged (with a metal clip) under sonography. In case of multiple suspicious nodes,
      the radiologist must choose the worst node in order to tag only one involved node.

      Then, then patients will perform their chemotherapy. The choice of NAC regimen is let at the
      discretion of each participating team.

      After NAC, breast tumor size and axillary assessment are performed.

      Breast and axillary surgery are performed during the same procedure, 4 to 6 weeks after
      completion of NAC. Breast surgery can be conservative or radical.

      All patients undergo the resection of the tagged axillary node, SLN biopsy and a
      complementary axillary lymphadenectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Anticipated">October 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>False negative rate</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>number of cases of false prediction of absence of lymph node involvement to the total number of cases with metastatic lymph node. The rate of FN will be calculated for the involved lymph node tagged with the metal clip, the sentinel node, and the both</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification rate of involved lymph node tagged</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>number of cases where the tagged lymph node with a metal clip node is identified during axillary surgery and analyzed in pathology on the total number of procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate of involved lymph node tagged</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>number of cases where the tagged lymph node is resected during axillary surgery and analyzed in pathology on the total number of procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>number of complications related to the axillary lymph node tagging procedure on the total number of procedures</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Invasive Breast Cancer</condition>
  <condition>Axillary Metastases</condition>
  <arm_group>
    <arm_group_label>Tagged axillary metastatic node</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.
The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tagged axillary metastatic node</intervention_name>
    <description>First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.
Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.
SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy.</description>
    <arm_group_label>Tagged axillary metastatic node</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years old

          2. Initial diagnosis of operable invasive breast carcinoma

          3. Histologically proven axillary metastasis (cytology or biopsy) before NAC

          4. Patient included in a therapeutic approach of neoadjuvant chemotherapy

          5. Procedure for the detection of sentinel lymph node by isotopic method +/- colorimetric

          6. Information of the patient and obtaining written consent, signed by the patient and
             the investigator

          7. Affiliated patient or beneficiary of the social security

        Exclusion Criteria:

          1. pT4d (inflammatory breast cancer)

          2. Metastatic breast cancer

          3. Any prior chemotherapy for contralateral breast cancer

          4. Local relapse of breast cancer

          5. Axillary metastasis not histologically proven before NAC

          6. Allergy known to the 2 detection products (Blue and radioactive tracer)

          7. Pregnant or lactating woman

          8. Neo Adjuvant chemotherapy contraindicated

          9. Patient protected or under guardianship or unable to give consent

         10. Impossibility of submitting to the medical examination for geographical, social or
             psychological
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JEAN-MARC CLASSE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO NANTES</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JEAN-MARC CLASSE, MD</last_name>
    <phone>+33240679910</phone>
    <email>Jean-Marc.Classe@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie DEBEAUPUIS</last_name>
    <phone>+33240679900</phone>
    <phone_ext>9048</phone_ext>
    <email>emilie.debeaupuis@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO - Site ANGERS</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinique Urbain</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène CHARITANSKY, MD</last_name>
      <email>h.charitansky@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François DUPRE, MD</last_name>
      <email>pierre-francois.dupre@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre GUIMBERGUES, MD</last_name>
      <email>pierre.gimbergues@cjp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francoise Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUTOWSKI Marian, MD</last_name>
      <email>marian.gutowski@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>APHP - Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte NGO, MD</last_name>
      <email>charlotte.ngo@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ico Nantes</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEAN-MARC CLASSE, MD</last_name>
      <phone>+332 40 67 99 10</phone>
      <email>jean-marc.classe@ico.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>CECILE LOAEC, MD</last_name>
      <phone>+332 40 67 98 22</phone>
      <email>Cecile.Loaec@ico.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>JEAN-MARC CLASSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CURIE</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugénie GUILLOT</last_name>
      <email>eugenie.guillot@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IUCT-O</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva JOUVE, MD</last_name>
      <email>Jouve.Eva@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérlogie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe RAUCH, MD</last_name>
      <email>p.rauch@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Sentinel lymph node</keyword>
  <keyword>Axillary lymphadenectomy</keyword>
  <keyword>Tagged axillary metastatic node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

